Compare ELME & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | SLN |
|---|---|---|
| Founded | 1960 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 236.2M |
| IPO Year | 1994 | N/A |
| Metric | ELME | SLN |
|---|---|---|
| Price | $2.15 | $6.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $12.67 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 1.1M | 195.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 33.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $206,360,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.10 | $1.97 |
| 52 Week High | $17.68 | $7.78 |
| Indicator | ELME | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 13.05 | 73.07 |
| Support Level | $2.10 | $5.79 |
| Resistance Level | $2.26 | $7.40 |
| Average True Range (ATR) | 0.03 | 0.57 |
| MACD | 0.24 | 0.18 |
| Stochastic Oscillator | 34.93 | 97.90 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.